European-Latin American TB Research Collaboration Network

Resultado final

report on TB mass screening activities in vulnerable, highly endemic populations

With the results from WP 4 and the mass screening report an in-depth analysis can be made from TB epidemiology in the penal institutions in Paraguay and measures may be discussed and prepared to decline the high TB incidence rates.

Systematic review and report

Systematic review and meta-analysis report of the in vivo and human experience of high dose rifampicin in DS-TB

Correlation report

Report on correlation of genetic polymorphisms, PK, treatment outcome in a mixed Paraguayan cohort and hard to treat patients from Europe and Latin America

Health care cost questionnaire

High dose rifampicin in vulnerable population report

Phase III Clinical trial protocol

we will review data regarding anti-TB drugs and make a reasoned decision about the best combination therapy to achieve a successful TB treatment outcome in a 4-month treatment duration. A study protocol, adapted to the circumstances present in Latin America and Europe, keeping all the international standards to ensure a high quality trial, will be designed. This design will especially prioritize low cost and simplicity compared to other aspects.

MGM workshop at INORMS conference

MGM staff from the consortium will provide a workshop on internationalising research at the INORMS conference 2020

external workshop pharmacogenetics

A workshop pharmacogenetic differences between Africans, Latin Americans and European TB patients will be given (at a conference)

Publicaciones

Dried Blood Spot Sampling to Assess Rifampicin Exposure and Treatment Outcomes among Native and Non-Native Tuberculosis Patients in Paraguay: An Exploratory Study

Autores: Samiksha Ghimire; Gladys Molinas; Arturo Battaglia; Nilza Martinez; Luis Gómez Paciello; Sarita Aguirre; Jan-Willem C. Alffenaar; Marieke G. G. Sturkenboom; Cecile Magis-Escurra
Publicado en: Crossref, Edición 1, 2023, ISSN 1999-4923
Editor: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics15041089

Safety of Rifampicin at High Dose for Difficult-to-Treat Tuberculosis: Protocol for RIAlta Phase 2b/c Trial

Autores: Juan Espinosa-Pereiro; Samiksha Ghimire; Marieke G. G. Sturkenboom; Jan-Willem C. Alffenaar; Margarida Tavares; Sarita Aguirre; Arturo Battaglia; Gladys Molinas; Teresa Tórtola; Onno W. Akkerman; Adrian Sanchez-Montalva; Cecile Magis-Escurra
Publicado en: Crossref, Edición 1, 2022, ISSN 1999-4923
Editor: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics15010009

Resultado final

Publicaciones

Compartir esta página

Descargar